GLP-1
On April 1, 2026, the FDA approved Foundayo (orforglipron) — and the GLP-1 landscape changed overnight. For the first time, patients can take an oral GLP-1 receptor agonist without any food or water restrictions. No 30-minute fasting window. No injection. Just a daily pill, taken whenever is convenient. But what exactly
GLP-1
Retatrutide targets three hormones — GLP-1, GIP, and glucagon — and has achieved 28.7% body weight loss in Phase 3 trials, rivaling bariatric surgery. Here's what you need to know.
GLP-1
For a moment in 2023 and 2024, Pfizer's danuglipron looked like it might democratize the GLP-1 revolution. An oral pill — no injections, no refrigeration, no weekly shot schedules — that could help millions lose significant weight. Then, in April 2025, Pfizer pulled the plug. One patient. One liver injury
GLP-1
Semaglutide (Ozempic, Wegovy, Rybelsus) is the world's most searched GLP-1 medication. This complete 2026 guide covers mechanism of action, dosing protocols, side effects, compounded semaglutide safety, and long-term cardiovascular outcomes.
GLP-1
In the rapidly evolving world of GLP-1 medications, a new contender is generating significant scientific interest — not just for how much weight it helps people lose, but for what kind of weight. Pemvidutide, developed by Altimmune under the research name ALT-801, is a once-weekly injectable dual agonist of the GLP-1
GLP-1
For years, people seeking GLP-1 therapy for weight loss faced a common obstacle: weekly injections. Now, that's changed. On April 1, 2026, the FDA approved orforglipron — sold under the brand name Foundayo — as the first oral, non-peptide GLP-1 receptor agonist for chronic weight management. No injections. No food
GLP-1
If the trajectory of weight-loss medicine over the past decade has felt like a steady upward climb, retatrutide feels like someone strapped a rocket to the ascent. Developed by Eli Lilly under the research code LY3437943, this investigational drug is the first triple-receptor agonist in clinical trials — hitting the GLP-1,
GLP-1
Two injectable medications are reshaping obesity medicine: tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy). Both belong to the GLP-1 drug class, both are once-weekly injections, and both produce clinically meaningful weight loss. But the similarities mostly end there. In May 2025, the landmark SURMOUNT-5 trial published in the New England
GLP-1
GLP-1
Cagrilintide & CagriSema: The Amylin+GLP-1 Combo Redefining Weight Loss (2026 Guide) For years, GLP-1 receptor agonists like semaglutide and tirzepatide dominated the conversation around obesity medicine. But a new class of combination therapy is forcing experts to rethink what's possible in weight loss pharmacology. CagriSema — a once-weekly
GLP-1
Semaglutide reduced body weight by nearly 15% in clinical trials and cut cardiovascular events by 20% in people with obesity and no diabetes. Here is the complete science-backed guide to Ozempic, Wegovy, and Rybelsus in 2026.
GLP-1
Retatrutide is the most powerful weight-loss drug ever tested in a clinical trial. In Phase 2 studies, patients lost up to 24.2% of their body weight in 48 weeks. In the first Phase 3 trial, average weight loss reached 71.2 pounds. Those numbers put every existing GLP-1 medication